Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 4Pancreatic Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × vandetanib × Gastrointestinal × Clear all
NCT00753675 2016-10-10

VANGOGH

Sanofi

Phase 2 Completed
174 enrolled 12 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT00551096 2013-12-25

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

University of Colorado, Denver

Phase 1 Completed
23 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡